Vivanza Biosciences Intrinsic Value
VIVANZA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹6.57 | ₹5.26 - ₹7.88 | +200.0% | EPS: ₹0.56, Sector P/E: 22x |
| Book Value Method | asset | ₹5.47 | ₹4.92 - ₹6.02 | +149.8% | Book Value/Share: ₹10.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹4.38 | ₹3.94 - ₹4.82 | +100.0% | Revenue/Share: ₹550.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹4.38 | ₹3.94 - ₹4.82 | +100.0% | EBITDA: ₹4.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹5.47 | ₹4.38 - ₹6.56 | +149.8% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹3.58 | ₹3.22 - ₹3.94 | +63.5% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹6.57 | ₹5.91 - ₹7.23 | +200.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹4.38 | ₹3.94 - ₹4.82 | +100.0% | ROE: 100.0%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹6.57 | ₹5.91 - ₹7.23 | +200.0% | EPS: ₹0.56, BVPS: ₹10.00 |
Want to compare with current market value? Check VIVANZA share price latest .
Valuation Comparison Chart
VIVANZA Intrinsic Value Analysis
What is the intrinsic value of VIVANZA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Vivanza Biosciences (VIVANZA) is ₹5.47 (median value). With the current market price of ₹2.19, this represents a +149.8% variance from our estimated fair value.
The valuation range spans from ₹3.58 to ₹6.57, indicating ₹3.58 - ₹6.57.
Is VIVANZA undervalued or overvalued?
Based on our multi-method analysis, Vivanza Biosciences (VIVANZA) appears to be trading below calculated value by approximately 149.8%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 4.25 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 100.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 1.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 12.94x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Vivanza Biosciences
Additional stock information and data for VIVANZA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |